Effects of Corticotropin‐Releasing Factor 1 Receptor Antagonism on In Vivo Dentate Gyrus Long‐Term Potentiation in the TgF344 ‐ AD Rat Model of Alzheimer's Disease
Hippocampus · 2026-05 · 36 (3)
DOI: 10.1002/hipo.70103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hippocampus, online erschienen am 20.05.2026. Verfasst von Nicole C Reyna und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, University of New Mexico, Albuquerque, New Mexico, USA. Hauptthemen laut MEDLINE: Dentate Gyrus, Long-Term Potentiation, Alzheimer Disease, Receptors, Corticotropin-Releasing Hormone. Die Arbeit nennt 74 Literaturangaben. Gefördert von: NIA NIH HHS, National Institute on Aging.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is characterized by irreversible neurobiological deterioration and cognitive impairment. AD patients exhibit stress system abnormalities including upregulation of the corticotropin releasing factor type 1 receptor (CRF 1 ) and elevated cortisol. Psychological distress increases the likelihood of AD diagnosis and hastens neurocognitive decline. Administration of the CRF 1 antagonist, Antalarmin, reduces AD pathogenesis and anxiety‐like behavior in models of AD. Motivated by these observations, the current study examined the potential contributions of CRF 1 to altered synaptic plasticity in AD neuropathology and stress in the TgF344‐AD rat model. In vivo electrophysiological recordings to assess long‐term potentiation (LTP) in the perforant pathway to dentate gyrus synapses were performed in aged transgenic rats and wild‐type (WT) controls (2–2.5 years). TgF344‐AD rats had abnormal LTP measures of field excitatory post‐synaptic potentials (fEPSP) and population spikes (PS). Treatment with Antalarmin did not alter LTP measures in TgF344‐AD or WT rats. These observations indicate that LTP in TgF344‐AD rats is reduced compared to WT rats and that acute treatment with a CRF 1 antagonist did not rescue LTP deficits. Future research should further examine the mechanism of CRF 1 in AD and implications of agonism or direct infusions of Antalarmin in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychology, University of New Mexico, Albuquerque, New Mexico, USA.
ORCID-Profile: Nicole C Reyna, Derek A Hamilton
Förderung
- NIA NIH HHS
- National Institute on Aging
Zitieren
APA
Reyna, N. C., & Hamilton, D. A. (2026). Effects of Corticotropin‐Releasing Factor 1 Receptor Antagonism on In Vivo Dentate Gyrus Long‐Term Potentiation in the TgF344 ‐ AD Rat Model of Alzheimer's Disease. Hippocampus, 36(3). https://doi.org/10.1002/hipo.70103
Vancouver
Reyna NC, Hamilton DA. Effects of Corticotropin‐Releasing Factor 1 Receptor Antagonism on In Vivo Dentate Gyrus Long‐Term Potentiation in the TgF344 ‐ AD Rat Model of Alzheimer's Disease. Hippocampus. 2026;36(3). doi:10.1002/hipo.70103
BibTeX
@article{Reyna2026,
author = {Reyna, Nicole C and Hamilton, Derek A},
title = {Effects of Corticotropin‐Releasing Factor 1 Receptor Antagonism on In Vivo Dentate Gyrus Long‐Term Potentiation in the TgF344 ‐ AD Rat Model of Alzheimer's Disease},
journal = {Hippocampus},
year = {2026},
volume = {36},
number = {3},
doi = {10.1002/hipo.70103}
}
EUVIMED